Bioxyne Limited (ASX:BXN)
Australia
· Delayed Price · Currency is AUD | Market Cap | 120.96M |
| Revenue (ttm) | 47.95M |
| Net Income (ttm) | 8.97M |
| Shares Out | 2.24B |
| EPS (ttm) | 0.00 |
| PE Ratio | 13.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,737,237 |
| Average Volume | 4,707,204 |
| Open | 0.0560 |
| Previous Close | 0.0590 |
| Day's Range | 0.0540 - 0.0570 |
| 52-Week Range | 0.0190 - 0.0620 |
| Beta | 0.69 |
| RSI | 67.72 |
| Earnings Date | Feb 25, 2026 |
About Bioxyne
Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingr... [Read more]
Financial Performance
Financial StatementsNews
Bioxyne Ltd (ASX:BXN) (Half Year 2026) Earnings Call Highlights: Record Revenue Surge and ...
Bioxyne Ltd (ASX:BXN) (Half Year 2026) Earnings Call Highlights: Record Revenue Surge and Strategic Market Expansion
Half Year 2026 Bioxyne Ltd Earnings Call Transcript
Half Year 2026 Bioxyne Ltd Earnings Call Transcript
IRW-News: Bioxyne Limited: Quartals-Aktivitäts-Report für den Zeitraum endend am 31. Dezember 2025 • news
IRW-PRESS: Bioxyne Limited: Quartals-Aktivitäts-Report für den Zeitraum endend am 31. Dezember 2025
Bioxyne Delivers Australia's First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities
Australian life sciences and health products company Bioxyne Limited (ASX: BXN) announced Wednesday that its fully-owned subsidiary, Breathe Life Sciences ( BLS), has successfully manufactured and de...